Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma

Immune checkpoint inhibitors have been approved as second-line therapy for patients with advanced urothelial carcinoma (UC). However, which patients will obtain clinical benefit remains to be determined. To identify predictive biomarkers for the pembrolizumab (PEM) response early during treatment, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Teshima, Taro, Kobayashi, Yukari, Kawai, Taketo, Kushihara, Yoshihiro, Nagaoka, Koji, Miyakawa, Jimpei, Akiyama, Yoshiyuki, Yamada, Yuta, Sato, Yusuke, Yamada, Daisuke, Tanaka, Nobuyuki, Tsunoda, Tatsuhiko, Kume, Haruki, Kakimi, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219027/
https://www.ncbi.nlm.nih.gov/pubmed/35765279
http://dx.doi.org/10.3892/ol.2022.13384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219027/
https://www.ncbi.nlm.nih.gov/pubmed/35765279
http://dx.doi.org/10.3892/ol.2022.13384

Ejemplares similares